|
| General Information |
| Business: |
We are a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our first product candidate, NeoCart, is being investigated in a Phase 3 clinical trial. NeoCart utilizes various aspects of our regenerative medicine platform to develop an innovative tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is an investigational product and has not been approved for sale in any jurisdiction, including the United States. We we have no other products that are approved for sale in the United States and currently we are not selling any other products that may be approved for sale in other jurisdictions. |
|
| Industry: |
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES |
|
| Employees: |
42 |
Founded: |
2000 |
|
| Contact Information |
| Address: |
830 Winter Street, 3rd Floor, Waltham, MA 02451, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -37.9 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
HSGX |
| Shares (millions): |
5.9 |
| Price Range: |
$11.00 - $11.00 |
| Est.$ Volume |
$ 65.0 mil |
| Manager / Joint Managers |
Cowen and Company/ Needham & Company/ Canaccord Genuity |
| Co Managers |
BTIG |
| Expected to Trade |
12/3/2014 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
